Proportion of women with baseline Hgb ≤10.5 g/dL who achieved a >2 g/dL increase

ELARIS UF-2

ORIAHNN

50%

(n=48)

Placebo

21%

(n=24)

P=0.02


Results were similar in ELARIS UF-1 [ORIAHNN (n=52): 62%, placebo (n=31): 16%, P<0.001].

The baseline Hgb in the anemic ORIAHNN-treated women evaluated in this endpoint was ≤ 10.5 g/dL

Over 90% of women with baseline Hgb ≤10.5 g/dL took supplemental iron.

During the ELARIS UF-1 and UF-2 trials 2 women (0.5%) had heavy menstrual bleeding and required blood transfusion due to anemia.